Republic of Korea-based biosimilar developer Celltrion, maker of Inflectra, has announced that it will launch a contract development and manufacturing business to develop novel agents alongside its biosimilar pipeline.
Republic of Korea-based biosimilar developer Celltrion, maker of Inflectra, has announced that it will launch a contract development and manufacturing business to develop novel agents alongside its biosimilar pipeline.
Celltrion said in a statement that the new undertaking will allow the company to collaborate and partner with research institutes and biotechnology firms to successfully commercialize innovative molecules, and partners would benefit from sharing in Celltrion’s accumulated development expertise.
The new effort will focus initially on the therapeutic areas that have “the greatest synergy with Celltrion’s portfolio,” namely inflammatory diseases, cancer, and cardiovascular disease.
The news follows closely on the heels of another announcement concerning partnerships for Celltrion; on May 30, 2018, the company signed an agreement with Yonsei University Health System (which includes 4 hospitals that serve 3 million outpatients and 1 million inpatients each year) to jointly develop and license fc-saxatilin, a proposed therapy for the treatment of ischemic stroke.
Saxatilin is a snake venom that exerts thrombolytic and antiplatelet effects by interacting with multiple integrins on platelets. The researchers developing the drug believe that fc-saxatilin, an Fc-fusion protein, could prevent vascular leakage in patients with ischemic stroke by regulating occludin expression in endothelial tight junctions.1
Celltrion expects that the market for drugs targeting ischemic stroke will grow by 6.8% per year until 2020, and it hopes that an eventually approved fc-saxatilin could compete with Genentech’s thrombolytic drug, alteplase (Activase), for a share of the market.
A Celltrion executive said in a statement, “In order to bolster our next-generation pipeline, in addition to the development of antibody biosimilars, we have continued efforts to explore platform technologies and new molecules in relation to the development of new biopharmaceuticals and synthetic drugs. Through the agreement with Yonsei University Health System, we will push for open innovation to secure new drug pipelines.”
Reference
1. Choi HJ, Kwon I, Kim NE, et al. Fc-saxatilin suppresses hypoxia-induced vascular leakage by regulating endothelial occludin expression. Thromb Haemost. 2017;117(03): 595-605. doi: 10.1160/TH16-06-0469.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.